Semnurpharma - Getting back to normalSemnurpharmaSemnurpharmaSemnurpharma

Getting back to normal

  • About
    • Overview
    • Leadership Team
    • Board of Directors
    • Our Culture
  • Partners
  • Chronic Back Pain
    • Chronic Back Pain
    • SP-102 (SEMDEXA™)
    • About our Studies
      • Phase 3 C.L.E.A.R.-2 Study
      • Phase 3 C.L.E.A.R. Study
      • Phase 2 Repeat Dose Study – SP102-03
      • Phase 1 PK/PD and Safety Study – SP-102
      • Pre-Clinical Study – SP-102
  • Science
    • Technology
    • Publications
    • Clinical Trials
  • Investors
    • Investor Overview
    • Presentation
    • News and Events
    • SEC Filings
    • Governance
    • Analyst Coverage
    • Contact Investor Relations
    • Stock Information
  • Join Our Team
  • Contact Us

board-of-directors

26
Sep
Date September 26, 2025

Henry Ji, PhD

Henry Ji brings 25+ years of experience in the biotechnology and life sciences industry. Dr. Ji is c...
Read More
Author [email protected]
26
Sep
Date September 26, 2025

Dorman Followwill

Dorman Followwill was Senior Partner of Transformational Health at Frost & Sullivan, a business cons...
Read More
Author [email protected]
26
Sep
Date September 26, 2025

Alexander Wu, PhD

Yue Alexander Wu is co-founder and CEO of Cothera Bioscience, Inc., a translation medicine and preci...
Read More
Author [email protected]
26
Sep
Date September 26, 2025

Jay Chun, MD, PhD

Jay Chun, M.D., Ph.D., has served as the Chief of Neurosurgery and Director of the Atlantic Health S...
Read More
Author [email protected]

 

  • Overview
  • Partners
  • Our Culture
  • Product
  • Publications
  • Join Our Team
  • Presentation
  • Contact Us

Connect, follow and have a conversation with us

  • 960 San Antonio Road, Palo Alto, CA, 94303
  • (650) 422-7515
  • [email protected]

Privacy Policy | Terms of Use | © 2026 All rights reserved.